Bordas at CPHI 2025: leadership and innovation in Diosmin and citrus flavonoids

CPHI is a strategic meeting for the pharmaceutical and nutraceutical sector. Our participation in this large-scale trade fair reaffirms our commitment to excellence and innovation within these sectors. This event, recognised as one of the main international meeting points, has allowed us to strengthen strategic alliances, share technological advances and consolidate our position as specialists in citrus flavonoids.

30% increase in visits to our stand

Bordas participated in the fair with a presentation that highlighted the work of our professionals, accompanied by a clean and welcoming environment, which spoke of what we know how to do, how we can enhance our customers’ formulations and achieve their success, under the main guarantees translated into quality seals.

The increase in visits to our stand by up to 30% compared to the previous edition reflects the growing interest of professionals in ingredients of proven quality, capable of adding real value to their formulations. This result confirms that the combination of innovation, proximity and trust is indeed an essential driver for the sustainable growth of the industry.

Diosmin and micronised Diosmin as benchmarks in high-performance formulations

Among the main focuses of interest at CPHI 2025, our flagship products stood out. Bordas’ Diosmin and micronised Diosmin, two fundamental ingredients in the development of effective solutions for vascular health and people’s well-being.

Both Diosmin and micronised Diosmin from Bordas are distinguished by their purity, stability and performance, guaranteeing consistent results in different pharmaceutical and nutraceutical applications. Micronised Diosmin, in particular, has gained prominence due to its greater bioavailability, which translates into more efficient absorption and better results. 

The growing interest from formulators confirms our position as a benchmark in the manufacture of citrus flavonoids, supported by high-precision production processes and a solid commitment to quality and sustainability

A stronger, more collaborative international agenda of shared growth

The increase in visitors was accompanied by an intensive agenda of meetings with customers, distributors and strategic partners. These meetings focused on exploring new collaboration opportunities, analysing market trends and sharing perspectives on future regulatory challenges.

Bordas would like to thank everyone who visited our stand because every conversation was an opportunity to listen, provide solutions and strengthen relationships. This collaborative approach allows us to anticipate the industry’s needs and offer ingredients that meet the highest standards of quality, traceability and efficacy. 

Global projection in citrus-derived flavonoids

Participation in CPHI 2025 underlines the importance of continuous innovation in our working model. We invest in applied research and technological development with the aim of improving process efficiency and the functionality of each ingredient we manufacture. 

Our technical team works with rigorous quality controls, ensuring that each batch of Diosmin and micronised Diosmin meets the most demanding specifications both nationally and internationally. This attention to detail allows us to maintain the trust of our customers. 

The positive outcome at CPHI 2025 confirms the strength of our international presence and the soundness of our strategy. We consolidate our leadership in the citrus-derived flavonoid market, reinforcing the trend towards the use of natural, effective and sustainable ingredients.

Diosmin and micronised Diosmin will continue to be clear examples of how science and nature can unite to offer high-value solutions.

Our vision is clear: to continue being the trusted partner for those who lead in formulating solutions for health and well-being, combining experience, technology and proximity to build a stronger future together with our partners.